Fulcrum Therapeutics, Inc. FULC

FULC Company Overview

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that modulate gene expression to address genetically defined diseases. The company operates within the biotechnology and pharmaceutical research industry, with a particular emphasis on rare diseases driven by aberrant gene regulation. Its approach is based on identifying druggable regulatory elements that control gene expression rather than directly targeting the gene product itself.

Founded in 2015, Fulcrum Therapeutics was established to commercialize insights from human genetics and epigenetics into precision medicines. The company went public in 2019 and has since advanced a pipeline centered on neuromuscular and hematologic rare diseases. Its strategy is differentiated by a platform designed to systematically discover targets that can restore normal gene expression patterns, positioning the company within a niche segment of precision genetic medicine.